NO152089B - Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-pyridon-3-karboksylsyrederivater - Google Patents
Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-pyridon-3-karboksylsyrederivater Download PDFInfo
- Publication number
- NO152089B NO152089B NO790165A NO790165A NO152089B NO 152089 B NO152089 B NO 152089B NO 790165 A NO790165 A NO 790165A NO 790165 A NO790165 A NO 790165A NO 152089 B NO152089 B NO 152089B
- Authority
- NO
- Norway
- Prior art keywords
- oxo
- ethyl
- acid
- dihydronicotinic
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 15
- -1 pyrrolyl- Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- SSHRVPMSFQLCAG-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine-5-carboxylic acid Chemical class OC(=O)C1=CNCCC1 SSHRVPMSFQLCAG-UHFFFAOYSA-N 0.000 claims description 2
- PESNWCFMIWRFJR-UHFFFAOYSA-N 1-ethyl-4-oxo-6-(4-pyrrolidin-1-ylphenyl)pyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(N2CCCC2)C=C1 PESNWCFMIWRFJR-UHFFFAOYSA-N 0.000 claims description 2
- CVXHXXJSTHFTCT-UHFFFAOYSA-N 1-ethyl-6-(4-methylsulfanylphenyl)-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(SC)C=C1 CVXHXXJSTHFTCT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- YDUFUKMTWRFNFC-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)-1-cyclopropyl-4-oxopyridine-3-carboxylic acid Chemical compound C=1C=C2OCOC2=CC=1C1=CC(=O)C(C(=O)O)=CN1C1CC1 YDUFUKMTWRFNFC-UHFFFAOYSA-N 0.000 claims description 2
- HBXCFZJFGXBNPH-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(OCO2)C2=C1 HBXCFZJFGXBNPH-UHFFFAOYSA-N 0.000 claims description 2
- AKBXSBHUDQHSJE-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(N(C)C)C=C1 AKBXSBHUDQHSJE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000005504 styryl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- OTCBYAQSZCSRHL-UHFFFAOYSA-N 1-ethyl-6-(3-nitrophenyl)-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=CC([N+]([O-])=O)=C1 OTCBYAQSZCSRHL-UHFFFAOYSA-N 0.000 claims 1
- PQCWXMCPSAAITG-UHFFFAOYSA-N 1-ethyl-6-[2-(4-methoxyphenyl)ethenyl]-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C=CC1=CC=C(OC)C=C1 PQCWXMCPSAAITG-UHFFFAOYSA-N 0.000 claims 1
- NEUHGQSWPQSVGM-UHFFFAOYSA-N 1-ethyl-6-[3-methyl-4-(methylamino)phenyl]-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(NC)C(C)=C1 NEUHGQSWPQSVGM-UHFFFAOYSA-N 0.000 claims 1
- PAEURXOUQOXCAX-UHFFFAOYSA-N 6-(4-acetamidophenyl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(NC(C)=O)C=C1 PAEURXOUQOXCAX-UHFFFAOYSA-N 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 4
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- DQIZKUMHBKFRKB-UHFFFAOYSA-N 1-ethyl-4-oxo-6-phenylpyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=CC=C1 DQIZKUMHBKFRKB-UHFFFAOYSA-N 0.000 description 3
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 3
- YOEBQJYTBWGBTO-UHFFFAOYSA-N 6-(4-chlorophenyl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(Cl)C=C1 YOEBQJYTBWGBTO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- FUTACNYXCNCZTF-UHFFFAOYSA-N methyl 2-(4-chlorophenyl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylate Chemical compound CCN1C=C(C(=O)OC)C(=O)CC1C1=CC=C(Cl)C=C1 FUTACNYXCNCZTF-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SZVWKIOCBZKYCG-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(Cl)C=C1 SZVWKIOCBZKYCG-UHFFFAOYSA-N 0.000 description 2
- BIBDTWJVWOSUHD-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-3-oxopent-4-enoate Chemical compound COC(=O)CC(=O)C=CC1=CC=C(Cl)C=C1 BIBDTWJVWOSUHD-UHFFFAOYSA-N 0.000 description 2
- JGIZTNNWWRPFSK-UHFFFAOYSA-N methyl 6-(4-chlorophenyl)-4-methoxyhexa-3,5-dienoate Chemical compound COC(=O)CC=C(OC)C=CC1=CC=C(Cl)C=C1 JGIZTNNWWRPFSK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- OPSXYAFWJPPHQK-UHFFFAOYSA-N 1,2,3,6-tetrahydropyridine-3-carboxylic acid Chemical class OC(=O)C1CNCC=C1 OPSXYAFWJPPHQK-UHFFFAOYSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- UOCCPTLETREDCP-UHFFFAOYSA-N 1-cyclopropyl-2-(4-methoxyphenyl)-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1N(C2CC2)C=C(C(O)=O)C(=O)C1 UOCCPTLETREDCP-UHFFFAOYSA-N 0.000 description 1
- IKDHBJPCSGCSKG-UHFFFAOYSA-N 1-cyclopropyl-6-(4-methoxyphenyl)-4-oxopyridine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C(C(O)=O)=CN1C1CC1 IKDHBJPCSGCSKG-UHFFFAOYSA-N 0.000 description 1
- KKSZXOUOLXAZHD-UHFFFAOYSA-N 1-ethyl-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(O)C=C1 KKSZXOUOLXAZHD-UHFFFAOYSA-N 0.000 description 1
- VSOZABDORHJKJW-UHFFFAOYSA-N 1-ethyl-2-(4-methoxyphenyl)-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(OC)C=C1 VSOZABDORHJKJW-UHFFFAOYSA-N 0.000 description 1
- VRWNLLLXIVNOQD-UHFFFAOYSA-N 1-ethyl-2-(4-methylsulfanylphenyl)-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(SC)C=C1 VRWNLLLXIVNOQD-UHFFFAOYSA-N 0.000 description 1
- WOOVFQSWJKYAAQ-UHFFFAOYSA-N 1-ethyl-2-[3-methyl-4-(methylamino)phenyl]-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(NC)C(C)=C1 WOOVFQSWJKYAAQ-UHFFFAOYSA-N 0.000 description 1
- GZOGMLPONQDJLS-UHFFFAOYSA-N 1-ethyl-4-oxo-2-phenyl-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=CC=C1 GZOGMLPONQDJLS-UHFFFAOYSA-N 0.000 description 1
- HQQRCPMZRSOBLO-UHFFFAOYSA-N 1-ethyl-4-oxo-2-pyridin-3-yl-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=CN=C1 HQQRCPMZRSOBLO-UHFFFAOYSA-N 0.000 description 1
- HFLHLTVNZJBRRY-UHFFFAOYSA-N 1-ethyl-4-oxo-6-pyridin-3-ylpyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=CN=C1 HFLHLTVNZJBRRY-UHFFFAOYSA-N 0.000 description 1
- GCKGTSAEHKXUID-UHFFFAOYSA-N 1-ethyl-4-oxo-6-pyridin-4-ylpyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=NC=C1 GCKGTSAEHKXUID-UHFFFAOYSA-N 0.000 description 1
- WZEVMSQCRFQUGF-UHFFFAOYSA-N 1-ethyl-6-(4-hydroxyphenyl)-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(O)C=C1 WZEVMSQCRFQUGF-UHFFFAOYSA-N 0.000 description 1
- YCVRGAXZRFMTJK-UHFFFAOYSA-N 1-ethyl-6-(4-methoxyphenyl)-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(OC)C=C1 YCVRGAXZRFMTJK-UHFFFAOYSA-N 0.000 description 1
- BYZKYAPWPMYLMI-UHFFFAOYSA-N 1-methoxy-4-oxo-6-phenylpyridine-3-carboxylic acid;o-methylhydroxylamine Chemical compound CON.CON1C=C(C(O)=O)C(=O)C=C1C1=CC=CC=C1 BYZKYAPWPMYLMI-UHFFFAOYSA-N 0.000 description 1
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 1
- ABWILOVGYVAPAD-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-1-cyclopropyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound C=1C=C2OCOC2=CC=1C1CC(=O)C(C(=O)O)=CN1C1CC1 ABWILOVGYVAPAD-UHFFFAOYSA-N 0.000 description 1
- XPUNETSACYSEEZ-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(OCO2)C2=C1 XPUNETSACYSEEZ-UHFFFAOYSA-N 0.000 description 1
- QZDWFKAKCCLWJQ-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=C(Cl)C=CC=C1Cl QZDWFKAKCCLWJQ-UHFFFAOYSA-N 0.000 description 1
- PENMZOZWYJOAHA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(OC)C(OC)=C1 PENMZOZWYJOAHA-UHFFFAOYSA-N 0.000 description 1
- CFDHHEBRLPGIMI-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)CC1C1=CC=C(Cl)C=C1 CFDHHEBRLPGIMI-UHFFFAOYSA-N 0.000 description 1
- FZFIHBKOMOYAID-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-methyl-4-oxo-2,3-dihydropyridine-5-carboxylic acid Chemical compound CN1C=C(C(O)=O)C(=O)CC1C1=CC=C(Cl)C=C1 FZFIHBKOMOYAID-UHFFFAOYSA-N 0.000 description 1
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- SIXYIEWSUKAOEN-UHFFFAOYSA-N 3-aminobenzaldehyde Chemical compound NC1=CC=CC(C=O)=C1 SIXYIEWSUKAOEN-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- UECXDZSFDGWNTH-UHFFFAOYSA-N 3-methyl-4-(methylamino)benzaldehyde Chemical compound CNC1=CC=C(C=O)C=C1C UECXDZSFDGWNTH-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PFODEVGLOVUVHS-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(C)CCN1C1=CC=C(C=O)C=C1 PFODEVGLOVUVHS-UHFFFAOYSA-N 0.000 description 1
- LOONFRKFJPYULD-UHFFFAOYSA-N 4-(dimethylamino)-3-methylbenzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1C LOONFRKFJPYULD-UHFFFAOYSA-N 0.000 description 1
- SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 1
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 1
- DATXHLPRESKQJK-UHFFFAOYSA-N 4-pyrrolidin-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCCC1 DATXHLPRESKQJK-UHFFFAOYSA-N 0.000 description 1
- MRVSXTHSWQKNJH-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=C(Cl)C=CC=C1Cl MRVSXTHSWQKNJH-UHFFFAOYSA-N 0.000 description 1
- FSQCLECWIGVZHF-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(OC)C(OC)=C1 FSQCLECWIGVZHF-UHFFFAOYSA-N 0.000 description 1
- SSXUWHGRDQXTIW-UHFFFAOYSA-N 6-(3-chlorophenyl)-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=CC(Cl)=C1 SSXUWHGRDQXTIW-UHFFFAOYSA-N 0.000 description 1
- BJLOOEZJWICGHP-UHFFFAOYSA-N 6-(4-chlorophenyl)-1-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(Cl)C=C1 BJLOOEZJWICGHP-UHFFFAOYSA-N 0.000 description 1
- JQCDLXVQBCDFNO-UHFFFAOYSA-N 6-[4-(dimethylamino)-3-methylphenyl]-1-ethyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C1=CC=C(N(C)C)C(C)=C1 JQCDLXVQBCDFNO-UHFFFAOYSA-N 0.000 description 1
- IAVBYBWZTWFCNY-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-1-methoxy-4-oxopyridine-3-carboxylic acid;o-methylhydroxylamine Chemical compound CON.CON1C=C(C(O)=O)C(=O)C=C1C1=CC=C(N(C)C)C=C1 IAVBYBWZTWFCNY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- SOGYZYMYZGPPRT-UHFFFAOYSA-N C(C)(=O)NC1=CC=C(C=C1)C=1N(C=C(C(=O)O)C(C1)=O)CC.C(C)N Chemical compound C(C)(=O)NC1=CC=C(C=C1)C=1N(C=C(C(=O)O)C(C1)=O)CC.C(C)N SOGYZYMYZGPPRT-UHFFFAOYSA-N 0.000 description 1
- UWZWYCUNHRDNKH-UHFFFAOYSA-N C(C)(C)(C)N1C=C(C(=O)O)C(C=C1C1=CC=CC=C1)=O.C(C)(C)(C)N Chemical compound C(C)(C)(C)N1C=C(C(=O)O)C(C=C1C1=CC=CC=C1)=O.C(C)(C)(C)N UWZWYCUNHRDNKH-UHFFFAOYSA-N 0.000 description 1
- JMBYBSHOWAULKB-UHFFFAOYSA-N C(C)N1C=C(C(=O)O)C(C=C1C1=CC(=CC=C1)C(F)(F)F)=O.C(C)N Chemical compound C(C)N1C=C(C(=O)O)C(C=C1C1=CC(=CC=C1)C(F)(F)F)=O.C(C)N JMBYBSHOWAULKB-UHFFFAOYSA-N 0.000 description 1
- LKQVOGYWILBWEX-UHFFFAOYSA-N COCCN1C=C(C(=O)O)C(C=C1C1=CC=CC=C1)=O.COCCN Chemical compound COCCN1C=C(C(=O)O)C(C=C1C1=CC=CC=C1)=O.COCCN LKQVOGYWILBWEX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- AOGWQWCDZBARBT-UHFFFAOYSA-N adamantan-1-amine;1-(1-adamantyl)-4-oxo-6-phenylpyridine-3-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(N)C3.C=1C(=O)C(C(=O)O)=CN(C23CC4CC(CC(C4)C2)C3)C=1C1=CC=CC=C1 AOGWQWCDZBARBT-UHFFFAOYSA-N 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UXMSSLOVDZCQBQ-UHFFFAOYSA-N cyclopropylmethanamine;1-(cyclopropylmethyl)-4-oxo-6-phenylpyridine-3-carboxylic acid Chemical compound NCC1CC1.C=1C=CC=CC=1C1=CC(=O)C(C(=O)O)=CN1CC1CC1 UXMSSLOVDZCQBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950007554 levmetamfetamine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- DBKLSMPMFQFKIV-UHFFFAOYSA-N methyl 1-ethyl-4-oxo-6-(4-pyrrolidin-1-ylphenyl)pyridine-3-carboxylate Chemical compound CCN1C=C(C(=O)OC)C(=O)C=C1C1=CC=C(N2CCCC2)C=C1 DBKLSMPMFQFKIV-UHFFFAOYSA-N 0.000 description 1
- OZBCMVXVAVQXPC-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylate Chemical compound CCN1C=C(C(=O)OC)C(=O)CC1C1=CC=C(OC)C(OC)=C1 OZBCMVXVAVQXPC-UHFFFAOYSA-N 0.000 description 1
- XJKBJDDNXKBPRC-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-3-oxo-5-(3,4,5-trimethoxyphenyl)pent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC(OC)=C(OC)C(OC)=C1 XJKBJDDNXKBPRC-UHFFFAOYSA-N 0.000 description 1
- QJLFXLFSPWDJKD-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-3-oxo-5-(4-pyrrolidin-1-ylphenyl)pent-4-enoate Chemical compound C1=CC(C=CC(=O)C(C(=O)OC)=CNCC)=CC=C1N1CCCC1 QJLFXLFSPWDJKD-UHFFFAOYSA-N 0.000 description 1
- QVFOEHVPDHSCJZ-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-3-oxo-5-phenylpent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=CC=C1 QVFOEHVPDHSCJZ-UHFFFAOYSA-N 0.000 description 1
- XRERRIIXULJOAL-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-3-oxo-5-pyridin-3-ylpent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=CN=C1 XRERRIIXULJOAL-UHFFFAOYSA-N 0.000 description 1
- KSUUVKFYHJNBJH-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-5-(4-hydroxyphenyl)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(O)C=C1 KSUUVKFYHJNBJH-UHFFFAOYSA-N 0.000 description 1
- OOCPZSFEIVSKCV-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-5-(4-methoxyphenyl)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(OC)C=C1 OOCPZSFEIVSKCV-UHFFFAOYSA-N 0.000 description 1
- IVNOQZKUPJLRGU-UHFFFAOYSA-N methyl 2-(ethylaminomethylidene)-5-(4-methylsulfanylphenyl)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(SC)C=C1 IVNOQZKUPJLRGU-UHFFFAOYSA-N 0.000 description 1
- BKRLHJCQYAWQCT-UHFFFAOYSA-N methyl 2-[(cyclopropylamino)methylidene]-5-(4-methoxyphenyl)-3-oxopent-4-enoate Chemical compound C=1C=C(OC)C=CC=1C=CC(=O)C(C(=O)OC)=CNC1CC1 BKRLHJCQYAWQCT-UHFFFAOYSA-N 0.000 description 1
- RYRZOJUPKOYKSC-UHFFFAOYSA-N methyl 2-[4-(dimethylamino)phenyl]-1-ethyl-4-oxo-2,3-dihydropyridine-5-carboxylate Chemical compound CCN1C=C(C(=O)OC)C(=O)CC1C1=CC=C(N(C)C)C=C1 RYRZOJUPKOYKSC-UHFFFAOYSA-N 0.000 description 1
- LNDZIQFNSBRIST-UHFFFAOYSA-N methyl 5-(1,3-benzodioxol-5-yl)-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C2OCOC2=C1 LNDZIQFNSBRIST-UHFFFAOYSA-N 0.000 description 1
- IYPDNXHYXYSYNV-UHFFFAOYSA-N methyl 5-(1,3-benzodioxol-5-yl)-2-[(cyclopropylamino)methylidene]-3-oxopent-4-enoate Chemical compound C=1C=C2OCOC2=CC=1C=CC(=O)C(C(=O)OC)=CNC1CC1 IYPDNXHYXYSYNV-UHFFFAOYSA-N 0.000 description 1
- JUEZXBOTTQNYPP-UHFFFAOYSA-N methyl 5-(2,6-dichlorophenyl)-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=C(Cl)C=CC=C1Cl JUEZXBOTTQNYPP-UHFFFAOYSA-N 0.000 description 1
- IQTBPDHJGYTSDR-UHFFFAOYSA-N methyl 5-(3,4-dimethoxyphenyl)-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(OC)C(OC)=C1 IQTBPDHJGYTSDR-UHFFFAOYSA-N 0.000 description 1
- PBPWQVXKXDAMGU-UHFFFAOYSA-N methyl 5-(3-chlorophenyl)-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=CC(Cl)=C1 PBPWQVXKXDAMGU-UHFFFAOYSA-N 0.000 description 1
- ONDLANNXONXESA-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-2-(dimethylaminomethylidene)-3-oxopent-4-enoate Chemical compound COC(=O)C(=CN(C)C)C(=O)C=CC1=CC=C(Cl)C=C1 ONDLANNXONXESA-UHFFFAOYSA-N 0.000 description 1
- VKLFKOFZOUAGQR-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-2-(methylaminomethylidene)-3-oxopent-4-enoate Chemical compound CNC=C(C(=O)OC)C(=O)C=CC1=CC=C(Cl)C=C1 VKLFKOFZOUAGQR-UHFFFAOYSA-N 0.000 description 1
- BCWOZNWPPAFBEY-UHFFFAOYSA-N methyl 5-[4-(dimethylamino)-3-methylphenyl]-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(N(C)C)C(C)=C1 BCWOZNWPPAFBEY-UHFFFAOYSA-N 0.000 description 1
- MVZKJPNQMHVHEG-UHFFFAOYSA-N methyl 5-[4-(dimethylamino)phenyl]-2-(ethylaminomethylidene)-3-oxopent-4-enoate Chemical compound CCNC=C(C(=O)OC)C(=O)C=CC1=CC=C(N(C)C)C=C1 MVZKJPNQMHVHEG-UHFFFAOYSA-N 0.000 description 1
- UIRKEFHMCBPTFL-UHFFFAOYSA-N methyl 6-(4-chlorophenyl)-1-ethyl-4-oxopyridine-3-carboxylate Chemical compound CCN1C=C(C(=O)OC)C(=O)C=C1C1=CC=C(Cl)C=C1 UIRKEFHMCBPTFL-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Foreliggende oppfinnelse vedrører analogifremgangsmåter ved fremstilling av terapeutisk aktive nye 4-pyridon-3-kar-boksylsyrederivater med den generelle formel
hvor R"<*>" betyr C^_g-alkyl, C-^^Q-cykloalkyl, C^.-^Q-cykloal-kyl- C^_g-alkyl,-C^_(--alkoksy eller C-^_g-alkoksy-C.g-alkyl, ;R er sventuelt med R 4 , R 5 og/eller R 6 substituert fenyl eller styrylrest eller en 3- eller 4-pyridylrest, ;R 4 og R 5 er halogen, trifluormetyl, hydroksy, alkoksy, C^_g-alkyltio, C^_g-alkyl, amino, acylamino, C'^_g-alkylamino, di-C^_g-alkylamino, nitro, en gjennom et ring-N- eller -C-atom bundet pyrrolyl-, pyrrolidinyl- eller 4-metylpiperazinylrest, eller begge restene R 4 og R 5 tilsammen C,_fi-alkylendioksy, og ;6 ;R er C1 , ,r-alkoksy,1 ,3 ;med den begrensning at R ikke er metyl nar R er fenyl, ;og salter av denne forbindelse. ;Fremgangsmåten ifølge oppfinnelsen er karakterisert ved;at man ;a) dehydrogenerer et 1,4,5,6-tetrahydronikotinsyrederivat ;med formel ;;1 3 ;hvor R og R har de ovenfor angitte betydninger, ;i 5,6-stilling, eller ;b) dehydrogenerer en lavere-alkylester av forbindelsen med formel II i 5,6-stilling og forsåper en erholdt ester, og ;om ønsket overfører de erholdte forbindelser med formel I ;i et salt. ;Eksempler på C-^_g-alkylgrupper som kan være rette eller for-grene te er metyl, etyl, propyl, isopropyl, butyl, sek.- el- ;ler tert.-butyl og oktyl, hvorunder metyl og etyl er fore-trukne, eksempler på C^_g alkylendioksy er metylen- og ety-lendioksy. Som C^-^Q-cykloalkylrest er cyklopropyl foretruk- ;ket. Uttrykket halogen omfatter fluor, klor, brom og jod. Acylgruppen i en acylaminorest stammer fortrinnsvis fra en alifatisk karboksylsyre spesielt en sådan med 1-6 C-atomer, f.eks. maur-, eddik- eller propionsyre. ;Aktuelle salter av forbindelsene med formel I er alkalime- ;tall-, jordalkalimetall- og (eventuelt substituerte) ammoni-umsalter og såfremt basiske substituenter foreligger i mole-kylet addisjonssalter med fysiologisk fordragelige, sterke uorganiske og organiske syrer som f.eks. saltsyre, svovel- ;syre, fosforsyre, metansulfonsyre eller p-toluensulfonsyre. ;Dehydrogeneringen ifølge oppfinnelsen av en forbindelse med formel II eller en lavere-alkylester derav ifølge fremgangsmåte-varianene (a) henh. (b) kan utføres ved i og for seg kjente metoder, gjerne med et substituert benzofenon som 2,3-di-klor-5,6-dicyan-l,4-benzokinon (DDQ) eller tetraklor-1,4-benzokinon (kloranil) i et inert organisk løsningsmiddel som metylenklorid, benzen eller dioksan, og innenfor et tem-peraturområde fra romtemperatur til reaksjonsblandingens til-bakeløpstemperatur. Generelt går man slik frem at man til løsningen av tetrahydronikotinsyrederivatet drypper en løs- ;ning av det substituerte benzokinon idet man passer på ;at ekvimolære mengder omsettes. Ved ufargede utgangsmateri- ;aler ser man lett slutten på reaksjonen ved en fargning av reaksjonsblandingen. Reaksjonsproduktet kan isoleres på vanlig måte fra blandingen og f.eks. renses ved omkrystal-lisasjon eller kromatografiske metoder. ;Utgangsforbindelsene med formel II kan fremstilles ved opp-varmning av et 2-(R^-aminometylen)-3-okso-4-pentensyrederi-vat med formel ;;hvor R"*" gg R har de ovenfor nevnte betydninger, hensiktsmessig i et inert polart aprotisk organisk løsnings-middel som f.eks. dimetylformamid (DMF), dimetylsulfoksyd, (DMSO) eller heksametylfosforsyretriamid. Løsningen oppvar-mes én til flere timer ved en temperatur fra ca. 100°C til tilbakeløpstemperaturen, hvorved ringslutning til 1,4,5,6-tetrahydropyridon finner sted.
Fremstillingen av forbindelsene III kan igjen skje på i og for seg kjent måte i en flertrinnssyntese ut fra aldehyder :n 3
med formel R -CHO.
I det følgende reaksjonsskjerna beskrives fremstillingen av l-etyl-6-fenyl-4-okso-l,4-dihydronikotinsyre fra benzaldehyd generisk og i eksempel 1 fremstillingen fra l-etyl-6-(4-klorfenyl)-4-okso-l,4-dihydronikotinsyre henholdsvis me-tylesteren derav i detalj.
Ved variasjon av utgangsaldehydet VII-1, estergruppen i tri-fenylfosfoniumforbindelsen eller aminet ved omsetning av en forbindelse IV-1 til en forbindelse III-l kan på analog måte prinsippielt alle forbindelser med formel II fremstilles.
Forbindelsene med formel I er farmakologisk aktive. De har antibakteriell aktivitet og/eller en stimulerende virkning på sentralnervesystemet, idet de er karakterisert ved lave akutte toksisiteter. Således er f.eks. l-etyl-4-okso-6-fenyl-1,4-dihydronikotinsyre virkningsmessig vesentlig over-legent overfor nomifensin ved omtrent samme LD^ Q, mens det adskiller seg fordelaktig fra d-amfetamin og d-metamfeta-min med omtrent like sterk virkning ved en vesentlig lavere LD5q (se tabell 1).
Hva angår de nye forbindelsenes antibakterielle aktivitet,
egner de seg spesielt som terapeutika ved urinveisinfeksjoner. Overfor kjente forbindelser med dette indikasjonsområdet,
f.eks. overfor nitrofurantoin, utmerker det seg ved øket aktivitet overfor spesielle inf eks jonskilder, eksempelvis Escherichia coli, (se tabell 2).
Forsøksrapport
Den antibakterielle virkningen til forsøkssubstansene ble bestemt i 90 volum-% M 9-medium [(Biochim. Biophys. Acta 76, 9 (1963) og 10 volum-% trypticase-soyavæske i dobbelte fortynningsrekker. Inokuleringen fant sted med IO<4> koloni-dannende enheter pr. ml medium. Etter en inkubasjonsvarig-het på 20 timer ved 37°C ble minstekonsentrasjonen bestemt som hemmet bakterievekst (minimal inhibitory concentration, MIC [ug/ml]). Resultatene er sammenfattet i tabell 3.
4-pyridon-3-karboksylsyrederivatene med formel I som fremstilles ifølge foreliggende oppfinnelse kan derfor anvendes ved terapi og profylakse av sykdommer, spesielt av bakterielle infeksjoner, samt for stimulering av sentralnervesystemet i form av farma-søytiske preparater med direkte eller retardert frigjøring av virkestoffet i blanding med en for oral, rektal eller parenteral applikasjon egnet organisk eller uorganisk inert bærer, f.eks. vann, gelatin, gummi arabicum, melkesukker, stivelse, magnesium-stearat, talkum, planteoljer, polyalkylenglykoler eller vaseliner.
De farmasøytiske preparatene kan foreligge i fast form, f.eks. som tabletter, drageer, suppositorier, kapsler, i halv-fast form, f.eks. som salver, eller i flytende form, f.eks. som løsninger, suspensjoner eller emulsjoner. Eventuelt er de ster-ilisert og henholdsvis eller inneholder ytterligere hjelpestoff-er som konserverings-, stabiliserings-, fukte- eller emulgerings-midler, midler for smaksforbedring, salter for endring av det osmotiske trykk eller puffersubstanser.
Fremstillingen av de farmasøytiske preparater kan skje på en-hver åpenbar måte for fagmannen, nemlig ved at man blander virkestoffet med den ikke-toksiske inerte bærer som er egnet for terapeutisk administrering og bringer den erholdte blan-
ding i den egnede galeniske form.
Som doseringsretningslinje kan for forbindelsene med formel I som terapeutiske midler angis en mengde på 10-100 mg/kg, fortrinnsvis ca. 50 mg/kg kroppsvekt pr. dag, som middel med virkning på sentralnervesystemet en mengde på 100 ug til 10 mg pr. kg.
EKSEMPEL 1
3 g l-etyl-6-(4-klorfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre-metylester ble oppvarmet i 50 ml benzen til 80° og dråpevis blandet med en benzenløsning av 4 g diklordicyanbenzochinon (DDQ) inntil ingen avfarging kunne observeres. Man avkjølte og frafiltrerte det derved utfalne krystallinske materiale.
Det erholdte materiale, en blanding av l-etyl-6-(4-klorfenyl)-4-okso-l,4-dihydronikotinsyremetylester med DDQ ble rørt med 20 ml IN natronlut ved romtemperatur i 30 min., den klare løs-ningen fortynnet med 50 ml isvann og surgjort. forsiktig med 0,5 N saltsyre til pH 6,5. Derved falt produktet ut i nesten ren form. Det ble omkrystallisert fra eddikester. Utbytte:2,1 g 1-etyl-6-(4-klorfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 215-217°C.
Utgangsmaterialet fikk man på følgende måte:
14 g 4-klorbenzaldehyd og 47 g <2-metoksy-3-(metoksy-karbonyl)-allyl>-trifenylfosfoniumbromid ble oppløst i 130 ml metylenklorid. Dertil satte man ved romtemperatur under god røring 100 ml 50%-ig vandig natronlut hvorunder man observerte temp-eraturstigning. Det ble rørt videre 20 min., man helte satsen på is og ekstraherte med metylenklorid. Resten som ble tilbake etter tørking med natriumsulfat og avdestillasjonen av løsnings-midlet ble krystallisert fra metanol, moderluten filtrert i heksan/eter (4:1 v/v) gjennom en kort kiselgelsøyle og det ut-krystalliserte produkt fra eluatet forenet med hovedproduktet. Totalutbytte: 23,5 g (93,3%) rent 5-(4-klorfenyl)-3-metoksy-2,4-pentadienkarboksylsyremetylester, smp. 69-72°C.
23,5 g 5-(p-klorfenyl)-3-metoksy-2,4-pentadienkarboksylsyremetyl-ester oppløst i 250 ml dioksan ble blandet med 150 ml 0,1 N svovelsyre og holdt i 3 timer på 100°C. Man avkjølte, ekstraherte med eddikester og krystalliserte etter tørking av løsning-en ved tilsetning av heksan. Man fikk 14,8 g (66,7%) 5-(4-klor-fenyl)-3-okso-4-pentensyremetylester, smp. 78-80°C.
14,8 g 5-(4-klorfenyl)-3-okso-4-pentensyremetylester ble oppløst i 100 ml benzen og blandet med NN dimetylformamid-dimetylacetal.
Man rørte den rødbrune løsningen i 3 0 min. ved 6 0°C, fjernet løsningsmidlet og overskuddet av reagens og fikk 5-(4-klorfenyl)-2-(dimetylaminometylen)-3-okso-4-pentensyremetylester i form av en rødbrun olje som ble omsatt videre i denne formen.
Den erholdte olje ble oppløst i 50 ml benzen og rørt med 100
ml av en mettet benzenløsning av etylamin ved romtemperatur i 30 min. Deretter ble løsningsmidlet fjernet og resten krystallisert fra eter/heksan. Man fikk 12,4 g (68% over to trinn) 2-(etylaminometylen)-5-(4-klorfenyl)-3-okso-4-pentensyremetyl-ester, smp. 7 8-80°C.
5,2 g 2-(etylaminometylen)-5-(4-klorfenyl)-3-okso-4-pentensyre-metylester i 50 ml dimetylformamid ble holdt i 3 timer ved 140-150°C. Etter fjerning av løsningsmidlet fikk man l-etyl-6-(4-klorfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyremetylester som enhetlig, oljeaktig rest.
På analog måte fikk man
- ut fra benzaldehyd og propylamin 4-okso-6-fenyl-l-propyl-1,4-dihydronikotinsyre, smp. 153-154°C, - ut fra benzaldehyd og isopropylamin l-isopropyl-4-okso-6-fenyl-l,4-dihydronikotinsyre, smp. 215-216°C, - ut fra benzaldehyd og butylamin l-butyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 119-120°C, - ut fra benzaldehyd og tert.-butylamin 1-tert.-butyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 295°C (spaltn.) - ut fra benzaldehyd og oktylamin l-oktyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 62-63°C, - ut fra benzaldehyd og cyklopropylmetylamin 1-(cyklopropyl-metyl)-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 177-179°C, - ut fra benzaldehyd og cyklopropylamin l-cyklopropyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 180-181°C, - ut fra benzaldehyd og cyklopentylamin l-cyklopentyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 188-190°C, - ut fra benzaldehyd og cykloheksylamin l-cykloheksyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 257-259°C, - ut fra benzaldehyd og 1-adamantylamin 1-(1-adamantyl)-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 248°C (spaltning), - ut fra benzaldehyd og 2-metoksyetylamin 1-(2-metoksyetyl)-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 144-146°C, - ut fra benzaldehyd og metoksylamin l-metoksy-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 193-194°C, - ut fra benzaldehyd og O-butyl-hydroksylamin 1-butyloksy-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 130-132°C, - ut fra 3-nitrobenzaldehyd og etylamin l-etyl-6-(3-nitro-fenyl)-4-okso-l,4-dihydronikotinsyre, smp. 242-243°C, - ut fra 3-aminobenzaldehyd og etylamin l-etyl-6-(3-amino-fenyl)-4-okso-l,4-dihydronikotinsyre, smp. 145-146°C, - ut fra 4-(dimetylamino)-benzaldehyd og metoksylamin 6-[4-(dimetylamino)-fenyl]-l-metoksy-4-okso-l,4-dihydronikotinsyre, smp. 224°C (spaltning), - ut fra 4-(dimetylamino)-benzaldehyd og O-butylhydroksyl-amin l-butoksy-6-[4-(dimetylamino)-fenyl]-4-okso-l,4-dihydronikotinsyre , smp. 155-157°C, - ut fra 4-acetamidobenzaldehyd og etylamin 6-(4-acetamido-fenyl)-l-etyl-4-okso-l,4-dihydronikotinsyre, smp. 237,5-239°C, - ut fra 3-(trifluormetyl)-benzaldehyd og etylamin 1-etyl-4-okso-6-[3-(trifluormetyl)-fenyl]-1,4-dihydronikotinsyre , smp. 186-188°C, - ut fra 4-(4-metylpiperazino)-benzaldehyd og etylamin l-etyl-6-[4-(4-metylpiperazino)-fenyl]-4-okso-l,4-dihydronikotinsyre , smp. 246-248°C, - ut fra p-metoksyzimtsyrealdehyd og etylamin l-etyl-6-(p-metoksystyryl)-4-okso-l,4-dihydronikotinsyre, smp. 237-238°C.
EKSEMPEL 2
800 mg l-etyl-6-(4-klorfenyl)-4-okso-l,4,5,6-tetrahydronikotin-syre i 20 ml benzen ble blandet dråpevis ved 80°C med en løs-ning av 1,5 g DDQ i 30 ml benzen til løsningen ikke lenger ble avfarget. Man avkjølte, frafiltrerte fellingen, løste den i 20 ml IN natronlut og surgjorde løsningen forsiktig med kald 0,5 N saltsyre til pH 6,5. Det utfalne, fargeløse produkt ble vasket med vann og så med eter. Utbytte 0,7 g (88%) l-etyl-6-(4-klorfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 214-215°C.
Utgangsmaterialet erholdtes ved at man løste 1,85 g av det ifølge eksempel 1 erholdte l-etyl-6-(4-klorfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyremetylester i 10 ml dioksan og 10 ml metanol og oppvarmet i nærvær av 2 0 ml IN natronlut i 3 timer under tilbakeløp. Man avkjølte, surgjorde med 0,5 N saltsyre, frafiltrerte de utfeldte krystaller og omkrystalliserte dem fra metanol/eter. Utbytte 1,3 g (74%), smp. 142-144°C.
EKSEMPEL 3
På analog måte med eksemplene 1 og 2 ble fra benzaldehyd 2-(etylaminometylen)-3-okso-5-fenyl-4-pentensyremetylester fremstilt med smp.' 92-94°C,denne ble syklisert og forsåpet til 1-etyl-4-okso-6-fenyl-1,4,5,6-tetrahydronikotinsyre, smp. 148-150°C, og deretter dehydrogenert til l-etyl-4-okso-6-fenyl-1,4-dihydronikotinsyre, smp. 166-167°C.
EKSEMPEL 4
I analogi til eksempel 1 ble 2-(etylaminometylen)-5-[4-(dimetyl-amino) f enyl] -3-okso-4-pentensyremetylester , smp. 129-130°C, fremstilt fra 4-(dimetylamino)benzaldehyd, denne ble cyklisert til l-etyl-6-[4-(dimetylamino)fenyl]-4-okso-l,4,5,6-tetrahydroniko-tinsyremetylester, smp. 35-87°C og dehydrogenert og forsåpet til l-etyl-6-[4-(dimetylamino)-fenyl]-4-okso-l,4-dihydronikotinsyre, smp. 258-259°C.
EKSEMPEL 5
I analogi til eksempel 1 ble fra 3-metyl-4-(dimetylamino)benzaldehyd fremstilt 2-(etylaminometylen)-5-[3-metyl-4-(dimetyl-amino) -f enyl] -3-okso-4-pentensyremetylester, smp. 98-100°C,
denne ble cyklisert til l-etyl-6-[3-metyl-4-(dimetylamino-fenyl]-4-okso-l,4,5,6-tetrahydronikotinsyremetylester, dehydrogenert til l-etyl-6-[3-metyl-4-(dimetylamino)-fenyl]-4-okso-l,4-dihydro-nikotinsyremetylester, smp. 132-134°C og forsåpet til l-etyl-6-[3-metyl-4-(dimetylamino)fenyl]-4-okso-l,4-dihydronikotinsyre, smp. 160-162°C.
EKSEMPEL 6
I analogi til eksemplene 1 og 2 ble fra 4-pyrrolobenzaldehyd fremstilt 2-(etylaminometylen)-3-okso-5-(4-pyrrolofenyl)-4-pentensyremetylester, smp. 119-121°C,denne ble cyklisert og forsåpet ti] l-etyl-6-(4-pyrrolofenyl)-4-okso-l,4,5,6-tetrahydronikotin-
syre og deretter dehydrogenert til l-etyl-6-(4-pyrrolofenyl)-4-okso-1,4-dihydronikotinsyre, smp. ^300°C.
EKSEMPEL 7
I analogi til eksemplene 1 og 2 ble fra 4-metoksybenzaldehyd fremstilt 2-(etylaminometylen)-3-okso-5-(4-metoksyfenyl)-4-pentensyremetylester,denne ble cyklisert og forsåpet til l-etyl-6-(4-metoksyfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre, smp. 173-174°C og derpå dehydrogenert til l-etyl-6-(4-metoksyfenyl)-4-okso-1,4-dihydronikot insyre, smp. 215-217°C.
EKSEMPEL 8
I analogi til eksemplene 1 og 2 ble fra 4-metoksybenzaldehyd fremstilt 2-(cyklopropylaminometylen)-5-(4-metoksyfenyl)-3-okso-4-pentensyremetylester, smp. 125-127°C, denne ble cyklisert og forsåpet til l-cyklopropyl-6-(4-metoksyfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre, smp. 137-139°,• og deretter dehydrogenert til l-cyklopropyl-6-(4-metoksyfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 159-161°.
EKSEMPEL 9
I analogi til eksemplene 1 og 2 ble fra 3,4-dimetoksybenzaldehyd fremstilt 2-(etylaminometylen)-5-(3,4-dimetoksyfenyl)-3-okso-4-pentensyremetylester, denne ble cyklisert til l-etyl-6-(3,4-dimetoksyfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyremetylester, smp. 134-135°C, forsåpet til l-etyl-6-(3,4-dimetoksyfenyl)-4-okso-1,4,5,6-tetrahydronikotinsyre, smp. 132-183°C og derpå dehydrogenert til l-etyl-6-(3,4-dimetoksyfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 232-234°C.
EKSEMPEL 10
I analogi til eksemplene 1 og 2 ble fra 3,4-metylendioksybenz-aldehyd fremstilt 2-(etylaminometylen)-5-(3,4-metylendioksyfe-nyl)-3-okso-4-pentensyremetylester, smp. 124-125°, denne ble cyklisert og forsåpet til l-etyl-6-(3,4-metylendioksyfenyl)-4-okso-1,4,5,6-tetrahydronikotinsyre, smp. 173-175°C og deretter dehydrogenert til l-etyl-6-(3,4-metylendioksyfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 269-270°C.
EKSEMPEL 11
I analogi til eksemplene 1 og 2 ble fra 3,4-metylendioksybenz-aldehyd fremstilt 2-(cyklopropylaminometylen)-5-(3,4-metylen-dioksyfenyl)-3-okso-4-pentensyremetylester, smp. 158-160°C, denne ble cyklisert og forsåpet til l-cyklopropyl-6-(3,4-metylendi-oksyf enyl ) -4-okso-l , 4 , 5 , 6-tetrahydronikotinsyre , smp. 122-124°C og deretter dehydrogenert til l-cyklopropyl-6-(3,4-metylendioksy-fenyl)-4-okso-l,4-dihydronikotinsyre , smp. 211-212°C.
EKSEMPEL 12
I analogi til eksemplene 1 og 2 ble fra 3,4,5-trimetoksybenz-aldehyd fremstilt 2-(etylaminometylen)-3-okso-5-(3,4,5-trimetoksy-fenyl)-4-pentensyremetylester i form av en olje, denne ble cyklisert til l-etyl-4-okso-6-(3,4,5-trimetoksyfenyl)-1,4,5,6-tetrahydronikotinsyremetylester og derpå dehydrogenert og forsåpet til l-etyl-4-okso-6-(3,4,5-trimetoksyfenyl)-1,4-dihydronikotinsyre, smp. 200-201°C.
EKSEMPEL 13
I analogi til eksemplene 1 og 2 ble fra 4-(metyltio)-benzaldehyd fremstilt 2-(etylaminometylen)-5-(4-metyltiofenyl)-3-okso-4-pentensyremetylester, denne ble cyklisert og forsåpet til 1-etyl-6-(4-metyltiofenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre, smp. 173-174°C, og deretter dehydrogenert til l-etyl-6-(4-me-tyltiofenyl) -4-okso-l , 4-dihydronikotinsyre, smp. 195-197°C.
EKSEMPEL 14
I analogi til eksemplene 1 og 2 ble fra p-hydroksybenzaldehyd fremstilt 2-(etylaminometylen)-5-(4-hydroksyfenyl)-3-okso-4-pentensyremetylester, denne ble cyklisert og forsåpet til 1-etyl-6-(4-hydroksyfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre og deretter dehydrogenert til l-etyl-6-(4-hydroksyfenyl)-4-okso-1,4-dihydronikotinsyre, smp. 243-245°C.
EKSEMPEL 15
I analogi til eksemplene 1 og 2 ble fra m-klorbenzaldehyd fremstilt 2-(etylaminometylen) -5- (3-klorf enyl) -3-okso-4-pentensyre-metylester, denne cyklisert og forsåpet til l-etyl-6-(3-klorf enyl)-4-okso-l, 4 ,5,6-tetrahydroniko.tinsyre , smp. 143-145°C,
og dehydrogenert til l-etyl-6-(3-klorfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 212-213°C.
EKSEMPEL 16
I analogi til eksemplene 1 og 2 ble fra 2,6-diklorbenzaldehyd fremstilt 2-(etylaminometylen)-5-(2,6-diklorfenyl)-3-okso-4-pentensyremetylester, denne ble cyklisert og forsåpet til 1-etyl-6-(2,6-diklorfenyl)-4-okso-l,4,5,6-tetrahydronikotinsyre og derpå dehydrogenert til l-etyl-6-(2,6-diklorfenyl)-4-okso-l,4-dihydronikotinsyre, smp. 200-201°C.
EKSEMPEL 17
I analogi til eksemplene 1 og 2 ble fra p-klorbenzaldehyd fremstilt 5-(4-klorfenyl)-2-(metylaminometylen)-3-okso-4-pentensyre-metylester, smp. 114-116°C, denne ble cyklisert og forsåpet til 6-(4-klorfenyl)-l-metyl-4-okso-l,4,5,6-tetrahydronikotinsyre, smp. 205-206°, og deretter dehydrogenert til 6-(4-klorfenyl)-1-metyl-4-okso-l,4-dihydronikotinsyre, smp. 275-280°C (spaltning) .
EKSEMPEL 18
I analogi til eksemplene 1 og 2 ble fra 3-metyl-4-metylamino-benzaldehyd fremstilt 2-(etylaminometylen)-5-(3-metyl-4-metyl-aminofenyl)-3-okso-4-pentensyremetylester, denne ble cyklisert og forsåpet til l-etyl-6-(3-metyl-4-metylaminofenyl)-4-okso-1,4,5,6-tetrahydronikotinsyre og derpå dehydrogenert til 1-etyl-6-(3-mety1-4-metyl a .rainofenyl)-4-okso-l,4-dihydronikotinsyre, smp. 243-244°C.
EKSEMPEL 19
I analogi til eksempelne 1 og 2 ble fra nikotinaldehyd fremstilt 2-(etylaminometylen)-3-okso-5-(3-pyridyl)-4-pentensyremetyl-ester, smp. 78-80°C, denne ble cyklisert og forsåpet til 1-etyl-4-okso-6-(3-pyridyl)-1,4,5,6-tetrahydronikotinsyre, smp. 197-199 C, og deretter dehydrogenert til l-etyl-4-okso-6-(3-pyridyl)-1,4-dihydronikotinsyre, smp. 209-210°C.
På analog måte ble fra isonikotinaldehyd fremstilt l-etyl-4-okso-6-(4-pyridyl)-1,4-dihydronikotinsyre, smp. 268-270°C.
EKSEMPEL 20
I analogi til eksemplene 1 og 2 ble fra 4-pyrrolidinobenzaldehyd fremstilt 2-(etylaminometylen)-3-okso-5-(4-pyrrolidinofenyl)-4-pentensyremetylester, denne ble cyklisert og forsåpet til 1-etyl-4-okso-6-(4-pyrrolidinofenyl)-1,4,5,6-tetrahydronikotin-
syre og deretter dehydrogenert til l-etyl-6-(4-pyrrolidinofenyl)-4-okso-l,4-dihydronikotinsyre, smp. 276-278°C.
Denne forbindelsen kan også erholdes på følgende måte:
7,8 g l-etyl-4-okso-6-(4-pyrrolofenyl)-1,4-dihydronikotinsyre-metylester hydrogeneres ved romtemperatur med 8,5 g 5%'ig palla-dium-på-karbon i 800 ml metanol. Etter fjerning av katalysatoren inndampes reaksjonsblandingen til tørrhet og resten opptas med metylenklorid. Den organiske løsning ekstraheres i iskald 1 N saltsyre, det vandige ekstrakt nøytraliseres med 1 N natronlut og ekstraheres med metylenklorid. Etter tørking av løsningen og inndampning får man 7,0 g l-etyl-4-okso-6-(4-pyrrolidinofenyl)-1,4-dihydronikotinsyremetylester, smp. 157-159°C (fra metanol).
I analogi til eksempel 1 kan esteren deretter forsåpes til sy-ren .
EKSEMPEL 21
Til en suspensjon av 172,7 mg l-etyl-4-okso-6-(2-metoksy-3,4-metylendioksyfenyl)-1,4-dihydronikotinsyreetylester (smeltepunkt 185-187°C) i 5 ml vann satte man 0,5 ml 1 N natronlut. Reaksjonsblandingen ble kokt 30 minutter under tilbakeløp og den faste resten omkrystallisert fra etanol etter fordampning av løsningsmiddelet. Man fikk 154,4 mg natriumsalt av l-etyl-4-okso-6-(2-metoksy-3,4-metylendi-oksyf enyl) -1 , 4-dihydronikotinsyre (spaltning ved 150°C).
Claims (3)
1. Analogifremgangsmåte ved fremstilling av terapeutisk aktive 4-pyridon-3-karboksylsyrederivater med den generelle formel
hvori R<1> betyr C^g-alkyl, C3_1()-cykloalkyl, C3_1Q-cyklo-
alkyl-C1_6-alkyl, C^g-alkoksy eller C^g-alkoksy-C,,--alkyl; 3 4 5 6 R en eventuelt med R , R og/eller R substituert
fenyl- eller styrylrest eller en 3- eller 4-pyridylrest; 4 5
R og R betyr halogen, trifluormetyl, hydroksy,
C1_g-alkoksy, C^g-alkyltio, C1_g-alkyl, amino, acylamino, C1_6~alkylamino, di-C-^g-alkylamino, nitro, en pyrrolyl-, pyrrolidinyl- eller 4-metylpiperazinylrest som er bundet gjennom et ring-N-4 5 eller -C-atom eller begge restene R og R betyr 6tilsammen C,_,-alkylendioksy; og
R betyr C1_6~alkoksy,
med den begrensning at R"<*>" ikke er metyl når R"^ er fenyl og salter av denne forbindelse, karakterisert ved at man a) i 5,6-strlling dehydrogenerer et 1,4,5,6-tetrahydronikotinsyrederivat med formel
hvor R og R^ har de ovenfor angitte betydninger, eller b) dehydrogenerer en lavere-alkylester av forbindelser med formel II og forsåper en erholdt ester,
og om ønsket overfører den erholdte forbindelse med formel I i et salt.
2. Fremgangsmåte ifølge krav 1 ved fremstilling av en av de følgende forbindelser: l-etyl-6-[4-(dimetylamino)-fenyl]-4-okso-l,4-dihydronikotinsyre ; il-etyl-6-(4-metoksyfenyl)-4-okso-l,4-dihydronikotinsyre; l-etyl-6-(3,4-metylendioksyfenyl)-4-okso-l,4-dihydronikotinsyre ;
l-cyklopropyl-6-(3,4-metylendioksyfenyl)-4-okso-l,4-dihydronikotinsyre ; l-etyl-6-(4-metyitiofenyl)-4-okso-l,4-dihydronikotinsyre; l-etyl-6-(3-metyl-4-metylaminofenyl)-4-okso-l,4-dihydronikotinsyre ; l-etyl-6-(4-pyrrolidinofenyl)-4-okso-l,4-dihydronikotinsyre, karakterisert ved at man dehydrogenerer til-svarende substituerte utgangsmaterialer.
3. Fremgangsmåte ifølge krav 1 ved fremstilling av en. av de folgende forbindelser: l-etyl-6- (3-nitrofenyl)-4-okso-l,4-dihydronikotinsyre; 6-(4-acetamidofenyl)-l-etyl-4-okso-l,4-dihydronikotinsyre; l-etyl-6- (p--metoksystyryl) -4-okso-l, 4-dihydronikotinsyre , karakterisert ved at man dehydrogenerer til-svarende substituerte utgangsmaterialer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH51278A CH639073A5 (en) | 1978-01-18 | 1978-01-18 | 4-Pyridone-3-carboxylic acid derivatives and their preparation |
CH1173478 | 1978-11-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO790165L NO790165L (no) | 1979-07-19 |
NO152089B true NO152089B (no) | 1985-04-22 |
NO152089C NO152089C (no) | 1985-08-14 |
Family
ID=25684790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO790165A NO152089C (no) | 1978-01-18 | 1979-01-17 | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-pyridon-3-karboksylsyrederivater |
Country Status (25)
Country | Link |
---|---|
US (2) | US4521535A (no) |
EP (1) | EP0003144B1 (no) |
JP (1) | JPS54100382A (no) |
KR (1) | KR820002111B1 (no) |
AR (1) | AR223663A1 (no) |
AT (1) | AT369731B (no) |
AU (1) | AU521148B2 (no) |
CA (1) | CA1110234A (no) |
DE (1) | DE2901868A1 (no) |
DK (1) | DK20279A (no) |
ES (1) | ES476917A1 (no) |
FI (1) | FI790103A (no) |
FR (1) | FR2415103A1 (no) |
GB (1) | GB2013190B (no) |
GR (1) | GR73088B (no) |
HU (1) | HU179487B (no) |
IE (1) | IE47784B1 (no) |
IL (1) | IL56421A (no) |
LU (1) | LU80794A1 (no) |
MC (1) | MC1239A1 (no) |
NL (1) | NL7900264A (no) |
NO (1) | NO152089C (no) |
NZ (1) | NZ189379A (no) |
PT (1) | PT69093A (no) |
SE (1) | SE7900318L (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1125762A (en) * | 1979-07-13 | 1982-06-15 | Alexander E. Wick | Dihydronicotinic acid derivatives and process for the preparation thereof |
ZA813029B (en) * | 1980-05-12 | 1982-05-26 | Rohm & Haas | Novel substituted oxonicotinates,their use as plant growth regulators and plant growth regulating compositions containing them |
US4964896A (en) * | 1980-05-12 | 1990-10-23 | Monsanto Company | Certain-2,6-diphenyl-1,4-dihydro-4-oxo-nicotinates which are useful for inducing male sterility in cereal grain plants |
US4936904A (en) * | 1980-05-12 | 1990-06-26 | Carlson Glenn R | Aryl-4-oxonicotinates useful for inducing male sterility in cereal grain plants |
US4714492A (en) * | 1980-05-12 | 1987-12-22 | Rohm And Haas Company | Certain 2-phenyl-4-oxo-nicotinates and their use for inducing male sterility in a cereal grain plant |
NZ201395A (en) * | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
DE3338846A1 (de) * | 1982-10-29 | 1984-05-03 | Toyama Chemical Co. Ltd., Tokyo | Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben |
JPS5980665A (ja) * | 1982-10-29 | 1984-05-10 | Toyama Chem Co Ltd | 4−オキソ−1,4−ジヒドロニコチン酸誘導体 |
GB8502424D0 (en) * | 1985-01-31 | 1985-03-06 | Pharis R P | Promotion of flowering fruit trees |
GB9317314D0 (en) * | 1993-08-20 | 1993-10-06 | Smithkline Beecham Corp | Compounds |
EP2149547A1 (en) * | 2008-07-30 | 2010-02-03 | LEK Pharmaceuticals D.D. | Process for the synthesis of ezetimibe and intermediates useful therefor |
WO2015099107A1 (ja) | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | 含窒素6員環誘導体およびそれらを含有する医薬組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907808A (en) * | 1971-05-17 | 1975-09-23 | Sterling Drug Inc | 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives |
IN142614B (no) * | 1974-08-28 | 1977-08-06 | Lilly Co Eli | |
CA1125762A (en) * | 1979-07-13 | 1982-06-15 | Alexander E. Wick | Dihydronicotinic acid derivatives and process for the preparation thereof |
DE3338846A1 (de) * | 1982-10-29 | 1984-05-03 | Toyama Chemical Co. Ltd., Tokyo | Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben |
-
1978
- 1978-12-28 CA CA318,702A patent/CA1110234A/en not_active Expired
-
1979
- 1979-01-11 AU AU43296/79A patent/AU521148B2/en not_active Ceased
- 1979-01-12 FI FI790103A patent/FI790103A/fi unknown
- 1979-01-12 IL IL56421A patent/IL56421A/xx unknown
- 1979-01-12 NL NL7900264A patent/NL7900264A/xx not_active Application Discontinuation
- 1979-01-15 MC MC791356A patent/MC1239A1/xx unknown
- 1979-01-15 NZ NZ189379A patent/NZ189379A/en unknown
- 1979-01-15 SE SE7900318A patent/SE7900318L/xx unknown
- 1979-01-15 HU HU79HO2130A patent/HU179487B/hu unknown
- 1979-01-16 FR FR7900974A patent/FR2415103A1/fr active Granted
- 1979-01-16 LU LU80794A patent/LU80794A1/de unknown
- 1979-01-16 JP JP233079A patent/JPS54100382A/ja active Pending
- 1979-01-16 GR GR58105A patent/GR73088B/el unknown
- 1979-01-17 PT PT7969093A patent/PT69093A/pt unknown
- 1979-01-17 AR AR275201A patent/AR223663A1/es active
- 1979-01-17 DK DK20279A patent/DK20279A/da not_active Application Discontinuation
- 1979-01-17 NO NO790165A patent/NO152089C/no unknown
- 1979-01-17 AT AT0035079A patent/AT369731B/de not_active IP Right Cessation
- 1979-01-17 GB GB7901668A patent/GB2013190B/en not_active Expired
- 1979-01-17 ES ES476917A patent/ES476917A1/es not_active Expired
- 1979-01-17 KR KR7900120A patent/KR820002111B1/ko active
- 1979-01-18 DE DE19792901868 patent/DE2901868A1/de not_active Withdrawn
- 1979-01-18 EP EP79100149A patent/EP0003144B1/de not_active Expired
- 1979-01-30 IE IE113/79A patent/IE47784B1/en unknown
-
1982
- 1982-04-19 US US06/369,778 patent/US4521535A/en not_active Expired - Fee Related
-
1984
- 1984-11-02 US US06/667,528 patent/US4549022A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK20279A (da) | 1979-07-19 |
US4549022A (en) | 1985-10-22 |
DE2901868A1 (de) | 1979-07-19 |
MC1239A1 (fr) | 1979-10-26 |
NO790165L (no) | 1979-07-19 |
ATA35079A (de) | 1982-06-15 |
EP0003144A3 (en) | 1979-08-08 |
FR2415103A1 (fr) | 1979-08-17 |
PT69093A (en) | 1979-02-01 |
IE47784B1 (en) | 1984-06-13 |
FI790103A (fi) | 1979-07-19 |
NO152089C (no) | 1985-08-14 |
LU80794A1 (de) | 1980-02-14 |
EP0003144A2 (de) | 1979-07-25 |
AU521148B2 (en) | 1982-03-18 |
SE7900318L (sv) | 1979-07-19 |
NZ189379A (en) | 1984-07-06 |
IL56421A0 (en) | 1979-03-12 |
ES476917A1 (es) | 1979-11-16 |
AT369731B (de) | 1983-01-25 |
GB2013190B (en) | 1982-07-14 |
AR223663A1 (es) | 1981-09-15 |
GB2013190A (en) | 1979-08-08 |
NL7900264A (nl) | 1979-07-20 |
KR820002111B1 (ko) | 1982-11-10 |
EP0003144B1 (de) | 1981-08-05 |
US4521535A (en) | 1985-06-04 |
JPS54100382A (en) | 1979-08-08 |
IE790113L (en) | 1979-07-18 |
HU179487B (en) | 1982-10-28 |
FR2415103B1 (no) | 1982-11-05 |
AU4329679A (en) | 1979-07-26 |
GR73088B (no) | 1984-02-01 |
CA1110234A (en) | 1981-10-06 |
IL56421A (en) | 1982-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5019575A (en) | Novel pyridazinone compounds, compositions thereof and method of use | |
US4110337A (en) | Triazolobenzodiazepines | |
NO152089B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-pyridon-3-karboksylsyrederivater | |
GB2127408A (en) | Improvements in or relating to benzimidazoles | |
JPH0316344B2 (no) | ||
JPH024761A (ja) | アリールヒドラゾン | |
HUT54360A (en) | Process for producing new naphthylalkyl-3h-1,2,3,5-oxathiadiazole-2-oxide derivatives and medical compositions comprising such compounds | |
US3487087A (en) | Nitration of imidazoles | |
IE920734A1 (en) | 4-aryl-thiazole or imidazole derivatives | |
US4612318A (en) | CNS-depressant and analgesic tricyclo-[pyrazolo-[3,4-6]-pyridine] derivatives and pharmaceutical compositions thereof | |
US4408047A (en) | Imidazodiazines | |
NO823026L (no) | 2(1h)-pyridinoner og fremgangsmaate for deres fremstilling | |
NZ201659A (en) | Benz-amino-1,2,4,5-tetrahydroimidazo(1,2-a)-quinazolin-2-ones | |
SU1311618A3 (ru) | Способ получени производных азулена | |
HU201015B (en) | Process for producing pyridine derivatives | |
NO164415B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5-acyl-2-(1h)-pyridinoner. | |
NO780059L (no) | Fremgangsmaate til fremstilling av terapeutisk virksomme forbindelser og preparater inneholdende disse | |
JPH05117273A (ja) | 医薬化合物 | |
US4801590A (en) | Pyrido(1,8)naphthyridinones, and their use as pharmaceuticals | |
US5238941A (en) | Arylhydrazones and pharmaceutical compositions thereof | |
IE41563B1 (en) | Sulfonamides | |
SU900808A3 (ru) | Способ получени аминопропанолпроизводных 6-окси-2,3,4,5-тетрагидро-1н-1-бензазепин-2-она или их солей | |
NO832810L (no) | 1,3-dioksolo(4,5-g)-kinoliner og fremgangsmaate for deres fremstilling. | |
JPS5817758B2 (ja) | 新規な2−アミノ−8−シクロプロピル−5−オキソ−5,8−ジヒドロ−ピリド〔2,3−d〕ピリミジン−6−カルボン酸化合物 | |
US4632924A (en) | 5-(4-substituted)phenyl-2-pyrazinones |